Toronto, Ontario – May 19, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce today that the Company has received Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) authorization to conduct a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) in the United States. Study II, entitled, “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Bacillus Calmette-Guerin (“BCG”)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Patients or Patients who are Intolerant to BCG Therapy” was successfully launched in Canada at 4 clinical study sites (with 1 additional clinical study site in advanced negotiation) and now with FDA IND authorization, the Company plans to launch approximately 15 clinical study sites … Read More

Toronto, Ontario – April 29, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, releases the audited annual consolidated financial statements for the year ended December 31, 2019. Financial Highlights: Total revenue for the year ended December 31, 2019 decreased $964,051 from $1,734,073 for the same period in 2018, a 44% decrease. The TLC-2000 represented 66% of sales in 2019 and 70% of sales in 2018. In Canada, revenue decreased 31% to $835,403 from $1,205,312. In the US, revenue decreased 68% to $96,574 from $304,785 and international revenue decreased 86% to $32,074 from $223,975. The decrease in total revenue in 2019 is due to the restructuring of the sales and marketing departments resulting in the resignation and/or termination of certain sales … Read More

Toronto, Ontario – March 20, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, has been notified by all of its Canadian clinical study sites that enrollment of new patients and conducting the first treatment procedure in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) has been temporarily placed on hold pending resolution of the coronavirus (“COVID-19”) global pandemic. Due to the global spread of COVID-19 and the uncertainty associated with the virus, the Company is in agreement with the clinical study site’s decision and with provincial and federal government recommendations concerning social distancing, to minimize hospital admittance to only patients with an emergency need. The clinical study sites have elected to temporarily halt enrollment and first treatment of patients in … Read More

Toronto, Ontario – February 25, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced that Nova Scotia Health Authority (“NSHA”) Research Ethics Board (“REB”) has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (“CIS”) and who are considered Bacillus Calmette Guerin(“BCG”)-Unresponsive or are intolerant to BCG Therapy (“Study II”). The Nova Scotia provincial cancer rates are among the highest in Canada. It is estimated for 2019 in Nova Scotia that 6,700 people were diagnosed with cancer, and 2,900 people died of cancer1 with bladder cancer cases counting for approximately 5% of cancer diagnosis.2 The NSHA institution is affiliated with the Urology Department at Dalhousie (“UDD”) University of Medicine, an innovative … Read More

Toronto, Ontario – February 20, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, is pleased to announce today that Theralase has been named a 2020 TSX Venture 50™ company. Presented by the TSX Venture Exchange, Theralase is ranked number eight in the Clean Technology & Life Sciences sector. This award recognizes the top 10 performing companies from five industry sectors selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount. Theralase was previously named a TSX Venture 50™ company in 2015 & 2019 making this the third year Theralase has been recognized as a top performer in the Clean Technology & Life Sciences sector. Shawn Shirazi, Ph.D., CEO of Theralase stated that “It is an honour to be recognized … Read More

Toronto, Ontario – January 27, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has been granted a U.S. Patent for Multiwavelength PhotoDynamic Therapy (“PDT”) technology. The U.S. patent entitled “Apparatus and Method for Multiwavelength Photodynamic Therapy” allows Theralase to use various laser wavelengths in the activation of PhotoDynamic Compounds (“PDC”) in cancerous tumours. The advantage is that a large or deep seated tumour may be only partially destroyed with laser of a particular wavelength, but then fully destroyed by employing one or two additional laser wavelengths, as different laser wavelengths are able to penetrate to different tissue depths. This would be especially important for cancers, such as Glio Blastoma … Read More

TORONTO, ON / January 16, 2020 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has won a precedent-setting lawsuit against anonymous internet posters for defamatory comments. The suit was filed due to false and disparaging statements posted online by anonymous individuals on the www.stockhouse.com bullboard from late 2014 through 2018. The libelous posts were defamatory not only to the Company, but also certain employees, specifically: Roger Dumoulin-White and Kristina Hachey on a personal level. The false and disparaging content of the posts were severe, including untrue allegations of criminal conduct by Mr. Dumoulin-White and Ms. Hachey and as a result denigrated their professional reputations. The decision of the Ontario Superior Court of Justice … Read More

Toronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy cancer, has announced significant benefits of its Rutherrin® (TLD-1433 + transferrin) formulation in comparison to a clinically approved PDC Amino Levulinic Acid (“ALA”), in the destruction of Rat Glioma (“RG2”) brain tumours, representative of GlioBlastoma Multiforme (“GBM”), a deadly form of human brain cancer. As previously disclosed, Theralase demonstrated that rats subjected to RG2 cancer cells, developed brain tumours representative of GBM. After intravenous (“IV”) injection of Rutherrin® and subsequent laser light activation, these animals survived significantly longer that animals who did not receive treatment and/or were treated with ALA-PDT. Further research conducted by Theralase researchers has demonstrated that Rutherrin® is able to provide a significant (up to 400 %) improvement in survival in animals treated with … Read More